+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 30Years +
MALE
ID07357259

Evaluating a Streamlined Dual-Phase 68Ga-PSMA PETCT Imaging Protocol to Reduce Radiation in High-risk Prostate Cancer

Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2026-01-21

244

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a modified dual-phase 68Ga-PSMA PETCT imaging method for patients with high-risk prostate cancer. This study compares a streamlined protocol that reduces radiation exposure and examination time against the standard imaging process. The goal is to maintain high diagnostic quality while improving patient experience and workflow efficiency in the Nuclear Medicine Unit. The trial includes patients newly diagnosed or experiencing biochemical recurrence of prostate cancer, with a focus on those with high-risk disease defined by Gleason Score 28 or PSA 20 ngmL. Participants are randomly assigned to one of two groups. The control group undergoes the conventional dual-phase PETCT protocol, including a whole-body scan at 60 minutes post-radiotracer injection followed by a delayed pelvic PETCT with CT at 90 minutes. The intervention group receives a standard whole-body PETCT at 60 minutes and a delayed pelvic PET-only scan at 90 minutes, using the initial CT scan for image correction to avoid repeat CT radiation. Patient repositioning is carefully performed to maintain alignment between the PET and CT images. During the study, three Medical Imaging Technologists independently evaluate the anatomical matching between delayed PET images and the CT dataset. Radiation dose exposure is measured, and patient comfort and waiting times are assessed through questionnaires. Departmental efficiency is monitored using scheduling records. The primary outcome is the quality of PET-CT matching, with secondary outcomes including radiation dose optimization and patient throughput. Participation lasts on average about one year until study completion.

CONDITIONS

Brief Title

Delayed Pelvic Imaging With [68]Ga-PSMA PET/CT in a Patient With High-risk Prostate Cancer.

Research Team

M

Michela Moscarino, Technician

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here